Objective
The RDAF works towards an improved access to diagnosis, treatment and care for patients living with a rare disease in Switzerland. With this aim in mind, the RDAF liaises with experts and policy makers to better consider the specificities of rare diseases in the Swiss legislative framework as well as the procedures for the assessment of treatment options. The Working Group was created in 2019 to support the initiatives of the RDAF by discussing relevant topics and defining potential solutions and action steps in a multi-stakeholder approach.
Activities
The Working Group:
Evaluates key areas of rare disease related policies and regulations and develops positions on relevant topics
Engages in outreach activities towards public authorities and other relevant stakeholders
Supports the RDAF in its activities such as the organization of the multi-stakeholder workshops.
An overview of the RDAF publications prepared by the Working Group can be found below. The full list of the RDAF publications is accessible on the publications page.
06 October 2021
RDAF statement on the Federal Council report on rare diseases
19 March 2021
RDAF statement for the public consultation on the adjustment of various ordinances which are needed to implement the revised Swiss Invalidity Insurance
10 December 2020
RDAF statement for the public consultation on he revision of the Federal Health Insurance Act concerning package 2 of the cost containment measures
Organization
The Working Group is composed of RDAF members and chaired by Rea Lal (Pfizer, Chair) and Andreas Uttenweiler (Takeda, Vice-Chair).
Rea Lal
Pfizer
Rea Lal
Pfizer
Working Group Chair
Andreas Uttenweiler
Takeda
Andreas Uttenweiler
Takeda
Working Group Vice-Chair